

INNOVA CAPTAB LIMITED
1281/1, Hilltop Industrial Estate, Near
EPIP, Phase-I, Jharmajri, Baddi, Dist.
Solan (H.P.)-173205 India.
Phone: +91-1795-650820



November 07, 2024

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001
BSE Symbol: INNOVACAP
BSE Scrip Code: 544067

To,
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C/1, "G" Block
Bandra-Kurla Complex
Bandra (E), Mumbai – 400 051
NSE Symbol: INNOVACAP

Dear Sir/Madam,

Subject: Press Release

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, ('SEBI LODR Regulations'), we are enclosing herewith the Press Release issued by the Company on the Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2024.

The Press Release is available on the website of the Company at www.innovacaptab.com

This is for your information and record.

Thanking you,

Yours faithfully,
For **Innova Captab Limited**

Neeharika Shukla
Company Secretary & Compliance Officer
Membership No.: A42724

Encl.: As above

INNOVA CAPTAB LIMITED

Press Release

Performance Review of Q2 and H1 FY25

Innova Captab Limited reported impressive results for Q2 FY25, with Revenue from Operations at ₹ 318.2 crores and Profit After Tax (PAT) at ₹ 35.0 crores

Registered YoY Revenue growth of 12.5% and PAT growth of 52.8%

Mumbai 7th November 2024: Innova Captab Limited (BSE: 544067, NSE: INNOVACAP) is a leading integrated pharmaceutical company committed to delivering high-quality healthcare solutions through a robust presence across the entire pharmaceuticals value chain, including research and development, manufacturing, distribution, marketing, and exports. The company is pleased to announce its financial results for the quarter and half-year ending September 30th, 2024.

Key Highlights

Q2 FY25 vs Q2 FY24

- Revenue from Operations was ₹ **318.2 crores** in the quarter vs ₹ **282.9 crores** last year, registering growth of **12.5%**
- EBITDA grew to ₹ **51.9 crores** vs ₹ **43.8 crores** last year. EBITDA Margins also improved to **16.3%** vs **15.5%** in Q2 FY24
- Profit after Tax improved significantly to ₹ **35.0 crores** vs ₹ **22.9 crores** (YoY growth of **52.8%**). PAT Margins improved to **11.0%** from **8.1%**

H1 FY25 vs H1 FY24

- Revenue from Operations grew **18.7%** to ₹ **612.5 crores** vs ₹ **516.2 crores** during same period in the previous year
- EBITDA increased to ₹ **96.2 crores** vs ₹ **76.2 crores** (YoY improvement of **26.2%**). EBITDA margins improved by **90 bps** to **15.7%**
- Profit after Tax grew by **59.2%** to ₹ **64.5 crores** vs ₹ **40.5 crores** in H1 FY24. PAT Margin increased to **10.5%** from **7.8%**

Commenting on the results, **Mr. Vinay Lohariwala, Managing Director – Innova Captab Limited** said “As we reflect on our Q2 and first half results for FY25, we are proud to report that our strategic initiatives are yielding tangible growth across all business areas, with a significant improvement in overall profitability.

In Q2 FY25, we achieved YoY revenue growth of 12.5%, while H1 FY25 saw an impressive increase of 18.7%. Our PAT demonstrated remarkable growth, with YoY growth of almost 53% in Q2 FY25 and 59% in H1 FY25.

We are particularly excited about the progress at our greenfield plant in Jammu, where we recently received ‘Drug Manufacturing License’ from Government of Jammu and Kashmir, Department of Health and Medical Education, Drug Control Organization, Jammu. With other necessary approvals in place, we had already begun manufacturing validation/ trial batches, and now with the receipt of the license, we expect commercialization of the facility within Q3 FY25e.

Additionally, we are establishing a new R&D facility in Panchkula, Haryana, which will further enhance our innovation capabilities.

Over the past few years, we have consistently demonstrated a high growth trajectory. With these initiatives and by leveraging our existing strengths, we are confident to continue to build growth momentum. We would like to thank our dedicated team and valued stakeholders for their ongoing support as we strive to create a sustainable and prosperous future for our company.”

Financial Performance

Q2 FY25 vs Q2 FY24

Particulars	Q2 FY25	Q2 FY24	YoY Growth
Revenue from Operations	318.2	282.9	12.5%
EBITDA	51.9	43.8	18.6%
EBITDA Margin (%)	16.3%	15.5%	80 bps
Profit before Tax	46.8	30.2	55.0%
Profit after Tax	35.0	22.9	52.8%

H1 FY25 vs H1 FY24

Particulars	H1 FY25	H1 FY24	YoY Growth
Revenue from Operations	612.5	516.2	18.7%
EBITDA	96.2	76.2	26.2%
EBITDA Margin (%)	15.7%	14.8%	90 bps
Profit before Tax	86.1	54.8	57.2%
Profit after Tax	64.5	40.5	59.2%

About Innova Captab Limited

Innova Captab Limited {Innova} (BSE: 544067, NSE: INNOVACAP) is an integrated pharmaceutical company in India with presence across the pharmaceuticals value chain including research and development, manufacturing, drug distribution and marketing and exports. Through its Contract Development and Manufacturing Organization (CDMO) segment, the company provides over 2,900 formulations to more than 190 pharmaceutical partners, including 14 of the top 15 companies in the Indian pharmaceuticals market. Innova's domestic branded generics business reaches 150,000 touchpoints, offering a diverse portfolio of over 600+ products. The company exports its finished formulations to more than 25 countries worldwide and operates four state-of-the-art manufacturing facilities accredited by leading global regulatory bodies like WHO-GMP, EU-GMP, UK-MHRA among others.

Additionally, Innova is expanding its capabilities with a greenfield project of establishing a multi-dosage plant in Jammu, India which will consist of 4 blocks – Cephalosporin, Penum, Penicillin and BFS. Together with this, the company will have total of 9 manufacturing blocks. Along with this, the company is also focussed on its R&D endeavours and is establishing a new R&D facility in Panchkula, Haryana in addition to the existing one in Baddi.

For more details, please visit www.innovacaptab.com

For more information, please contact:

Mr. Lokesh Bhasin / Ayush Kumar Garg

Email: investors@innovacaptab.com / ayush.garg@innovacaptab.com

DISCLAIMER:

Certain statements that are made in the Press Release may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in the economic environment in India and overseas, tax laws, inflation, litigation, etc. Actual results might differ substantially from those expressed or implied. Innova Captab Ltd. will not be in any way responsible for any action taken based on such statements and discussions; and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.